A preparation for improving the menstrual cycle of patients with polycystic ovary syndrome

A polycystic ovary and menstrual cycle technology, applied in the field of medicine, can solve the problems of no menstrual cycle research and achieve the effect of improving menstrual cycle and pregnancy rate

Active Publication Date: 2022-04-08
HEILONGJIANG UNIV OF CHINESE MEDICINE
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, the focus of the above patents or patent applications is mainly on PCOS itself, and there is no research on the menstrual cycle caused by PCOS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A preparation for improving the menstrual cycle of patients with polycystic ovary syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1: Tablet Composition

[0020] Isobuthrenone 2g

[0021] Berberine Hydrochloride 1g

[0022] Microcrystalline Cellulose 20g

[0023] Lactose 20g

[0024] Starch 6g

[0025] Talc powder 1.5g

[0026] Magnesium stearate 0.5g

[0027] Preparation method: mix the berberine hydrochloride, isubuthrenone, microcrystalline cellulose and lactose in the amount shown in the formula and granulate with 10 mg / ml gelatin solution, then sieve the wet granules and dry, then mix with Starch, talcum powder and magnesium stearate are mixed, sieved, and compressed into tablets, each containing berberine hydrochloride 0.01g.

Embodiment 2

[0028] Example 2: Tablet Composition

[0029] Isobuthrenone 2g

[0030] Berberine Hydrochloride 1.5g

[0031] Microcrystalline Cellulose 20g

[0032] Lactose 20g

[0033] Starch 6g

[0034] Talc powder 1.5g

[0035] Magnesium stearate 0.5g

[0036] Preparation method: mix the berberine hydrochloride, isubuthrenone, microcrystalline cellulose and lactose in the amount shown in the formula and granulate with 10 mg / ml gelatin solution, then sieve the wet granules and dry, then mix with Starch, talcum powder and magnesium stearate are mixed, sieved, and compressed into tablets, and each tablet contains berberine hydrochloride 0.015g.

Embodiment 3

[0045] Embodiment 3 animal pharmacodynamics experiment

[0046] 1 Animal model construction and administration

[0047] 70-day-old healthy and clean female SpraguDawley (SD) rats were selected to establish the polycystic ovary syndrome (PCOS) rat model according to the Poretsky method, and 3.0 U / d of human chorionic gonadotropin (HCG) was injected subcutaneously twice a day. From day 1 to day 10, the injection of intermediate-acting insulin started from 0.5U / d and gradually increased to 6.0U / d, and then injected at this dose every day. After 22 days, the levels of testosterone and insulin in the blood of the rats increased and the vaginal smears continued to appear angular. Cellular cells are in line with the PCOS model.

[0048] After successful modeling, 80 female rats with modeling results were divided into 4 groups, 20 in each group, respectively experimental group 1, experimental group 2, comparative group 1 and control group; 20 rats were used as blank group.

[0049]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a preparation for improving the menstrual cycle of patients with polycystic ovary syndrome. The invention uses isubuthrenone and berberine hydrochloride as therapeutic active ingredients in a specific ratio to make an oral preparation. It is proved by experiments that the combination of the two has Synergistically improve the menstrual cycle of polycystic ovary syndrome patients, and the results of clinical experiments further confirm that the pharmaceutical preparation of the present invention can significantly improve the menstrual cycle of polycystic ovary syndrome patients with oligomenorrhea or amenorrhea, and increase their pregnancy rate.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a preparation for improving the menstrual cycle of patients with polycystic ovary syndrome and an application thereof. Background technique [0002] Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women, accounting for 4% to 12% of women of reproductive age. It is clinically manifested as a syndrome of oligomenorrhea or amenorrhea, obesity, hirsutism, infertility, and bilateral polycystic ovarian enlargement. The typical endocrine features are hyperandrogenemia, increased plasma luteinizing hormone (LH) levels, and LH / FSH (follicle-stimulating hormone) ratio increased, estrone (E1) increased. It is also accompanied by hyperinsulinemia, peripheral insulin resistance, and abnormal lipidemia. So far, the etiology of PCOS is still unknown. Current research suggests that PCOS is a syndrome with genetically heterogeneous features that may resu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4375A61K31/4439A61P15/00A61P15/08A61K31/138A61K31/155A61K31/34A61K31/427
CPCA61K31/4375A61K31/34A61P15/00A61P15/08A61K31/4439A61K31/138A61K31/155A61K31/427A61K2300/00
Inventor 张春兰孙淼郝松莉孟小钰
Owner HEILONGJIANG UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap